Ipilimumab/nivolumab‐induced pseudolymphoma in a patient with malignant melanoma. (13th November 2019)

• Record Type: Journal Article
• Authors: Ayoubi, Noura; Haque, Adel; Vera, Nora; Ma, Sophia; Messina, Jane; Khushalani, Nikhil; Seminario‐Vidal, Lucia
• Is Part Of: Journal of cutaneous pathology. Volume 47:Number 4(2020)
• Page Start: 390
• Page End: 393
• Publication Date: 2019-11-13
• Subjects: drug rash -- ipilimumab -- melanoma -- nivolumab -- oncodermatology -- pseudolymphoma; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616
• DOI: 10.1111/cup.13604
• Languages: English
• ISSNs: 0303-6987

Abstract

Abstract: Combination therapy with ipilimumab and nivolumab is an adjuvant treatment approach for metastatic melanoma that boasts increased 3‐year survival when compared with a single immunotherapy agent. Combination therapy, however, is associated with increased toxicities, especially cutaneous side‐effects. Here we present a patient with metastatic melanoma and a sudden eruption of painful nodules on the face and arms 10 days after the administration of the fourth dose of combination ipilimumab/nivolumab. Biopsies demonstrated lymphoid hyperplasia, not clinically or pathologically consistent with an infectious, malignant or autoimmune etiology; a diagnosis of pseudolymphoma secondary to ipilimumab/nivolumab was made. After a steroid taper, the lesions resolved, and the patient was restarted on nivolumab monotherapy 2 weeks later without recurrence of symptoms or disease.